Venetoclax Plus LDAC May Benefit Patients with AML Ineligible for Intensive Chemotherapy
A new study evaluated combination venetoclax and low-dose cytarabine in previously untreated acute myeloid leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: John Schieszer Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Leukemia | Study